Latest annual · FY2025
Millions- Total revenues
- 7,513
- Net income
- 1,829
- Free cash flow
- 2,101
Latest quarter · Q3 FY2026
Millions- Total revenues
- 2,052
- Net income
- 579
- Free cash flow
- 684
Daily close · KEYIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions21.43 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +1.1%
- Revenue, 5 yearsFY2020 to FY2025
- +2.3%
- Net income, 5 yearsFY2020 to FY2025
- +6.4%
KEYCORP /NEW/ (KEY) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $7.5 billion | $4.6 billion | +62.7% | 10-K 2026-02-23 · proof |
| Net income | $1.8 billion | -$161 million | 10-K 2026-02-23 · proof | |
| Cash from operating activities | $2.2 billion | $664 million | +232.5% | 10-K 2026-02-23 · proof |
| Free cash flow | $2.1 billion | $599 million | +250.8% | 10-K 2026-02-23 · proof |
| Total assets | $184.4 billion | $187.2 billion | -1.5% | 10-K 2026-02-23 · proof |
| Total liabilities | $164 billion | $169 billion | -3% | 10-K 2026-02-23 · proof |
| Cash and cash equivalents | $1.3 billion | $1.7 billion | -26.2% | 10-K 2026-02-23 · proof |
- What was KEYCORP /NEW/ (KEY)'s revenue in fiscal 2025?
- KEYCORP /NEW/ (KEY) reported revenue of $7.5 billion for fiscal 2025 (the year ended Dec 31, 2025), against $4.6 billion the year before (+62.7%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What was KEYCORP /NEW/ (KEY)'s net income in fiscal 2025?
- KEYCORP /NEW/ (KEY) reported net income of $1.8 billion for fiscal 2025 (the year ended Dec 31, 2025), against -$161 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What was KEYCORP /NEW/ (KEY)'s cash from operating activities in fiscal 2025?
- KEYCORP /NEW/ (KEY) reported cash from operating activities of $2.2 billion for fiscal 2025 (the year ended Dec 31, 2025), against $664 million the year before (+232.5%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What was KEYCORP /NEW/ (KEY)'s free cash flow in fiscal 2025?
- KEYCORP /NEW/ (KEY) reported free cash flow of $2.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against $599 million the year before (+250.8%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What are KEYCORP /NEW/ (KEY)'s total assets?
- As of Dec 31, 2025, KEYCORP /NEW/ (KEY) reported total assets of $184.4 billion, against $187.2 billion a year earlier (-1.5%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What are KEYCORP /NEW/ (KEY)'s total liabilities?
- As of Dec 31, 2025, KEYCORP /NEW/ (KEY) reported total liabilities of $164 billion, against $169 billion a year earlier (-3%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What are KEYCORP /NEW/ (KEY)'s cash and cash equivalents?
- As of Dec 31, 2025, KEYCORP /NEW/ (KEY) reported cash and cash equivalents of $1.3 billion, against $1.7 billion a year earlier (-26.2%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:KEY&period_type=annual&limit=5"Information only, not investment advice.